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Summary. In 38 traumatic knee joint effusions the 
proteolytic enzyme PMN-elastase (PMN-E) and 
the repair marker procollagen III aminoterminal 
peptide (PIIINP) were determined. According to 
the period between trauma and first aspiration of 
the effusion, the patients were divided into 
3 groups. Group I (17 patients; period between 
trauma and first aspiration not longer than 
72 hours) showed high concentrations of PMN-E 
(up to 5400 ng/ml) and low concentrations of 
PIIINP (< 13 U/ml). Group II (11 patients; aspi- 
ration within 4 to 14 days) had mean PMN-E and 
PIIINP concentrations of 125.6 ng/ml and 52.1 U/ 
ml, respectively. In group III (10 patients, aspira- 
tion after 14 days) mean PMN-E concentration 
was 123.8 ng/ml and mean PIIINP concentration 
was 63.4 U/ml. Graphic depiction of PMN-E and 
PIIINP levels in each individual sample as a func- 
tion of time between trauma and fluid collection 
revealed highly increasing PMN-E levels during 
the first 24 posttraumatic hours, followed by rapid- 
ly decreasing levels within 72 hours post trauma, 
and no change after the 4th posttraumatic day. 
In contrast, PIIINP increased continuously up to 
the first posttraumatic week and stayed 'at high 
levels up to 90 days (end of the observation peri- 
od). The differential patterns of PMN-E and 
PIIINP concentration i  knee joint effusions may 
be useful in estimating the period between trauma 
and first treatment (aspiration of effusion) and 
should, therefore, be helpful in detecting degenera- 
tive lesions, which seem to be characterized bylow 
PMN-E concomitantly with high PIIINP levels. 
Key words: Traumatic knee joint effusion - PMN- 
elastase - Type III procollagen peptide 
Abbreviations: PMN-E=elastase from polymorphonuclear 
granulocytes; PIIINP = procollagen III aminoterminal peptide; 
~IPI = el-proteinase inhibitor 
The extracellularly released lysosomal serine pro- 
teinase elastase (PMN-E) from polymorphonuc- 
lear (PMN) granulocytes plays an important role 
as a nonspecific mediator of local inflammation 
by degrading a variety of matrix proteins in situ 
until being inhibited by its main antagonist cq-pro- 
teinase inhibitor [14, 19]. Large amounts of elas- 
tase (9947_+ 124 mg/1) were measured in complex 
with cq-proteinase inhibitor in close relation to the 
number of granulocytes in the inflammatory syno- 
vial fluid of patients uffering from arthritis [16]. 
Moreover, following knee injury the activity of ly- 
sosomal enzymes in synovial fluids increased with 
the extent of trauma [9]. In contrast to destructive 
processes involved in the inflammatory response, 
repair and healing is characterized bythe prolifera- 
tive phase of the synovial tissue. Augmented syn- 
thesis of collagen is thus detectable by increasing 
levels of porcollagen peptides, for example of 
type III aminoterminal procollagen peptide 
(PIIINP), in the joint fluid [10]. The N-terminal 
propeptide (Col 1-3, Mr 45 000) is cleaved off in 
a stoichiometric manner during the conversion of 
procollagen to collagen and is, therefore, consid- 
ered as a marker of tissue remodeling [11, 21, 22, 
26]. 
The goal of this prospective study was to find 
out whether acute and chronic traumatic knee joint 
effusions induced by sports injuries can be charac- 
terized by PMN-E and PIIINP concentrations in 
relation to the onset of trauma. 
Patients and Methods 
In the period of January to March 1990, knee joint 
effusions of 38 patients uffering from sports inju- 
ries were aspirated. The mean age of the patients 
was 30 years, ranging from 14 to 59 years. With 
regard to trauma history, these 38 patients could 
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be divided into three groups (Table 1). Group 1 
consisted of 17 patients with acute fr sh lesions, 
in whom aspiration was performed within 
72 hours. In the 11 patients of group II, aspiration 
was performed within 4 to 14 days, and for the 
10 patients of group III, the period between trau- 
ma and aspiration was longer than 14 days. All 
patients underwent arthroscopy and/or arthro- 
tomy for ligament and/or meniscal repair (Ta- 
ble 2). 
The samples were anticoagulated (1 ml citrate 
to 9 ml effusion), and centrifuged at 1500 g for 
ten minutes. Aliquots of the cell-free supernatant 
were immediately frozen and stored at -70  ~ C for 
up to 6 months until assayed. 
PMN-E in synovial fluids in complex with cd- 
proteinase inhibitor (cdPI) was determined accord- 
ing to Neumann [20] using a specific two-site sand- 
wich ELISA (Merck, Darmstadt, Germany). 
Moreover, to detect proteolytically active elastase 
which may not be inhibited in the local inflamma- 
tory environment due to lack of sufficient inhibito- 
ry active ~aPI, one part of each synovial fluid was 
mixed with a surplus of purified c~lPI and reas- 
sayed for an in vitro increase of the elastase-elPI 
complex. 
PIIINP was determined by a new version (RIA- 
ghost Procollagen III Peptide; Behringwerke, Mar- 
burg, Germany, Prod. No. OCFK) of the radioim- 
munoassy originally described by Rohde [23]. The 
new test system (IRMA) uses the principle of a 
2-stage sandwich assay. A complex of solid-phase 
bound monoclonal antibodies against PIIINP 
(Col 1-3), PIIINP in the sample, and ~25I-labelled 
monoclonal nti-PIIINP antibodies i formed dur- 
ing the assay procedure. At the end of reaction 
(incubation times were reduced by us to 3 h) the 
free tracer is removed and the amount of tracer 
specifically bound to the coated tubes is measued 
with a gamma scintillation counter. The mono- 
clonal antibodies used in the kit are highly specific 
for the peptide Col 1-3. The possibility of a cross- 
reaction with other basal membrane proteins that 
are physiologically relevant can be virtually ruled 
out. Cross-reactivity with proteolytic degradation 
products (Col 1, Mr 10000) is about 10% (product 
information, Behringwerke). 1 U/ml measured 
with the new test version corresponds to about 
15 ng/ml quantified with the original procedure 
(own data obtained from 50 serum samples mea- 
sured with both assay versions). 
Since the test kit is constructed primarily to 
quantify PIIINP in plasma or serum samples, we 
first checked the reliability of the assay to measure 
PIIINP adequately in snyovial fluids. For this, 
Table 1. Demographic data of 38 patients with traumatic knee 
joint effusions. With regard to the period between trauma and 
first aspiration, patients were divided into three groups. Data- 
are given as mean and range 
Group I Group II Group III 
Patients n = 17 n = 11 n = 10 
Female/male 3/14 6/5 1/9 
Mean age 24 + 4 28 + 7 36 + 13 
(years) (14-36) (2043) (18-59) 
Days after 1.7 8 29 
trauma (1-3) (4-14) (15-90) 
Table 2. Knee joint effusions and the arthroscopically con- 
firmed lesions of 38 patients with sports injuries ( ee also Ta- 
ble 1). In group II and group III, i.e., the older lesions, concom- 
itant cartilage damages increased 
Group I Group II Group III 
Hemarthrosis 17 5 2 
Serous effusion - 6 8 
Rupture of anterior 12 1 2 
cruciate ligament 
Rupture of 9 2 -- 
collateral ligament 
Tear of meniscus 7 7 11 
Flake fracture 7 2 2 
Damage of cartilage - 6 10 
samples of synovial fluid with a low PIIINP 
amount (< 2 U/ml) were spiked with 5 or 10 U/ml 
of the PIIINP standard. The recovery was 86 and 
92%, respectively. In addition, a sample of syno- 
vial fluid containing about 10 U PIIINP/ml (quan- 
tified by using the normal standard curve for serum 
samples) was diluted according to the standards 
of the kit. Both the standards and the synovial 
fluid dilutions gave similar slopes. In citrated plas- 
ma samples, the intraassay variations for mean 
values of 2.1, 8.8, and 17.4 U/ml were 2.4, 3.1 and 
1.9%, respectively; the interassay variation for
mean value of 1.8 U/ml was 5.6%. 
Data are expressed as mean + standard evia- 
tion and range. Using the Kruskal-Wallis test P 
values < 0.05 were considered significant. 
Results 
In group I, all patients (n = 17) had a hemarthrosis 
of 42 + 27 (12-110) ml. Severe combined knee joint 
lesions were detected by arthroscopy. In 12 cases 
acute anterior cruciate ligament ruptures were 
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Table 3. Mean and standard eviation of PMN-E and PIIINP 
concentrations i  knee joint effusions of 38 patients with sports 
9 injuries (see also Table 1) and of the aspirated volume. Group I
showed significantly (*) different values of PMN-E and PIIINP 
compared with group II or group III 
Group I Group II Group III p-value 
PMN-E ng/ml 2251 125.6 123.8 <0.005 
__+1647" +38.4 ___66.1 
PIIINP U/ml 5.7 52.1 63.4 <0.005 
___3.3* +38,4 -+28,7 
Volume ml 42 32 32 > 0.05 
-+27 -+26 _+12 
found. Biochemical analysis revealed elastase-~lPI 
concentrations of 2251+_1647 (121-5439) ng/ml 
and PIIINP levels of 5.7 +__ 3.3 (1.8-12.3) U/ml (Ta- 
ble 3). Yet, no proteolytically active elastase was 
measurable in these synovial fluid samples. 
In group II (n = 11), 6 synovial effusions, 4 san- 
guinary effusions, and one pure hemarthrosis were 
aspirated. The volume was 32_+26 (10-90) ml. 
Meniscus tear was the most frequently found knee 
joint lesion, only very seldom combined with liga- 
ment ruptures. In 6 cases concomitant cartilage 
damages were seen. Elastase-~lPI concentrations 
of 125.6 + 38.4 (83-202) ng/ml and PIIINP concen- 
trations of 52.1 + 38.4 (13-120) U/ml were quanti- 
fied in this group of patients (Table 3). 
In the 10 patients of group III, 8 synovial effu- 
sions of 32_+12 (15-65) ml were aspirated, and 
the mostly revealed lesions were meniscus tears. 
In all these 10 patients advanced cartilage damages 
were found (Table 2). The level of complexed elas- 
tase was 123.8+66.1 (60-331) ng/ml and that of 
PIIINP was 63.4-t-28.7 (31-133) U/ml (Table 3). 
Thus, traumatic knee joint effusions contain 
high concentrations of PMN-E (up to 5400 ng/ml) 
and low concentrations (< 13 U/ml) of PIIINP in 
the case of acute injuries. In contrast, a low con- 
centration of PMN-E (up to 330 ng/ml) and a high 
concentration (up to 133 U/ml) of PIIINP were 
measured in chronic injuries. 
Although no serial synovial fluid samples could 
be taken from our patients, the graphic depiction 
of PMN-E and PIIINP values in each individual 
sample as a function of time between trauma and 
sample collection shows the following character- 
ization of the posttraumatic period (Fig. 1) : PMN- 
E levels increased to a maximum within the first 
24 hours, then decreased rapidly during the next 
48 hours and stayed at a relatively low range after 
the 4th posttraumatic day. In contrast, PIIINP lev- 
els continuously increased up to the first posttrau- 
matic week, and no significant decrease was mea- 
sured during the further observation period of 
nearly 90 days. Statistical calculation (Kruskal- 
Wallis test) revealed (Table 3) that concentrations 
of elastase in group I were significantly higher than 
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Fig. 1. Concentrations (vertical bars=range) of PMN-elastase (in complex with el-proteinase inhibitor; n/ml) and procollagen 
III pepfide (U/ml) in traumatic knee joint effusions (n = 38) related to the period between trauma nd first aspiration. Traumatic 
knee joint effusions are characterized by high levels of elastase immediately after trauma (group I) and by increasing PIIINP 
and highly elevated concentrations, respectively, in the following period (groups II and III) 
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those in group II or III (p < 0.005), but there was 
no difference between groups II and III (p < 0.4). 
Similarly, a significant difference between concen- 
trations of PIIINP in group I compared to group 
II or IIII (p_<0.005) could be evaluated, but no 
difference between groups II and III with regard 
to PIIINP concentrations. Age, sex, or aspirated 
volume had no influence (p > 0.05). 
Discussion 
After trauma, the presence of a hemarthrosis 
a sign of severe joint lesion. Hemarthrosis leads 
to synovial hypertrophy and siderosis, which indi- 
cates the synovial cells are capable phagocytosis 
of erythrocytes and hemoglobin. In order to form 
siderosomes, the phagocytic ells have to synthe- 
size lysosomes containing destructive enzymes [5]. 
In contrast, phagocytic PMN granulocytes and 
monocytes attracted to the inflammatory focus 
contain already preformed lysosomes with active 
proteinases (e.g., elastases and cysteine protein- 
ases). Therefore, an increase in extracellularly re- 
leased lysosomal enzyme activity may be expected 
in traumatic knee joint effusions, since during the 
phagocytic process these enzymes are also dis- 
charged from the cells. 
In synovial fluids of patients with rheumatoid 
arthritis, three different fractions of elastase-type 
enzymes were found: (1) a serine type (originating 
from PMN granulocytes or monocytes), (2) a me- 
tallo type (from monocytes/macrophages), and (3) 
a fraction (of unknown origin) which was resistant 
to both serine enzyme and metallo enzyme inhibi- 
tors [6]. Inflammatory synovial fluids of rheuma 
patients are characterized by constantly very high 
elastase levels (mean: 9947 + 124'ng/ml) compared 
with elastase l vels of 41 + 0.5 ng/ml in non-inflam- 
matory synovial fluids [16]. From in vitro and in 
vivo studies it is known that the lysosomal serine 
enzyme elastase of PMN granulocyte is able to 
cleave a large number of substrates, for example 
matrix proteins [19] or IgG in rheumatic fluids 
[4]. In vivo extracellularly discharged PMN-E is 
rapidly complexed by the plasma inhibitors el-pro- 
teinase inhibitor (90%) and c~2-macroglobulin 
(10%). Therefore, in biological fluids, especially 
in plasma, elastase is measured primarily as the 
inactive enzyme in complex with cq-proteinase in- 
hibitor [12, 20]. Yet, in inflammatory local body 
fluids the inhibitory potential may be consumed 
to such a degree that proteolytically active elastase 
is also present [1, 13]. 
In our 38 joint effusions induced by sports inju- 
ries, the extracellularly released lysosomal serine 
proteinase lastase from PMN granulocytes in 
complex with el-proteinase inhibitor showed high 
levels (up to a mean of 2280 ng/ml) during the 
first 48 hours after the traumatic event, whereas 
after a longer interval (more than 4 days) between 
injury and effusion sampling, clearly elevated elas- 
tase levels could be no longer detected. This is in 
accordance with results of another study, where 
concentration of complexed elastase, leukocyte 
count, and the activity of several other lysosomal 
enzymes were found to increase with the severity 
of joint lesions reaching maximum mean values 
(PMN-E: 3940 +__1009 ng/ml) two to three days 
after trauma, followed by a significant decrease 
over the next few days [9]. In a further study carti- 
lage damages, tears of meniscus or ligament rup- 
tures due to injuries were associated with a dramat- 
ic release of proetoglycan fragments to the synovial 
fluids during the acute posttraumatic phase. These 
elevated levels of fragments gradually decreased 
over time [17, 18]. Interestingly, a similar behavior 
was shown in our study for the extracellularly re- 
leased elastase, which is known as one of the most 
potent lysosomal enzymes inducing the breakdown 
of proteoglycans. Although no proteolytically ac- 
tive elastase was measurable in any of our synovial 
fluid samples, one can assume that at least for a 
very short time high amounts of discharged elas- 
tase may be able to degrade humoral and structural 
proteins until the enzyme activity is eventually 
blocked by cdPI [2, 25]. 
During the inflammatory proliferative phase, 
synovial tissue is also characterized by stimulated 
syntheis and deposition of types I and III collagen 
as an indication of repair processes [7]. The in- 
creased synthesis of collagen is accompanied by 
detectable l vels of collagen in the joint fluid, the 
amount of collagen being roughly proportional to 
the degree of cartilage loss as assessed radiologi- 
cally [3]. During the conversion of procollagen to 
collagen, the type III aminoterminal procollagen 
peptide (PIIINP) is cleaved off in a stoichiometric 
manner [26]. Therefore, PIIINP may be considered 
as a marker of tissue remodeling and repair [10]. 
Measurement of PIIINP in serum has been sug- 
gested as a useful tool in the diagnosis and follow- 
up of various fibrotic conditions, particularly of 
liver diseases [24]. Yet, increased serum levels of 
PIIINP and its degradation products were found 
also in patients with rheumatoid arthritis [8, 10, 
11, 12]. Patients with active disease howed higher 
serum PIIINP levels than patients with inactive 
disease or healthy individuals. Therefore, the 
PIIINP serum level seems to reflect disease activity 
in rheumatoid arthritis and was suggested to be 
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a valuable prognostic marker in such disorder [10]. 
In contrast, PIIINP concentrations in synovial 
fluids from patients with inflammatory (e.g., rheu- 
matoid arthritis, septic arthritis) and non-inflam- 
matory (e.g., arthrosis, traumatic lesions) joint dis- 
eases did not reveal signifiant differences. Mean 
values were shown to be more than 1,000 times 
higher than in serum under both pathological con- 
ditions [8]. In 41 synovial fluid samples of non- 
inflammatory joint diseases due to traumatic le- 
sions or arthrosis, these values varied between ap- 
proximately 190 ng/ml and 2,900 ng/ml, with a 
mean of 1,390 ng/ml. Taking into account that 
15 ng/ml quantified by the authors [8] using the 
original test version from Behringwerke corre- 
sponds to 1 U/ml measured with our test system, 
the range of PIIINP levels would have been be- 
tween 13 to 194 U/ml. This is in accordance with 
the results obtained in group II and III patients 
(sample collection from the 4th to the 90th post- 
traumatic day) of our study (PIIINP range: 13 to 
133 U/ml). In contrast, PIIINP levels in synovial 
fluids of our group I patients (sample collection 
within 72 h post trauma) ranged only from 1.8 to 
12.3 U/ml with a mean of 5.7 U/ml probably indi- 
cating "normal" PIIINP levels in this early post- 
traumatic phase. Although "normal" synovial 
fluid was not available to us, this assumption is
based on the only slightly varying PIIINP values 
throughout this time and on results published by 
Horselev-Petersen et al. [10] who measured 162 ng/ 
ml (corresponding to about 11 U/ml) in a synovial 
fluid sample obtained from a healthy woman, 
whereas patients with reactive arthritis showed 
highly elevated synovial fluid PIIINP levels (497- 
2,441 ng/ml comparable to 33-142 U/ml). Yet, an- 
other cause for the low PIIINP levels in the first 
three posttraumatic days should be also taken into 
account. Since highly elevated extracellularly re- 
leased PMN-E could be measured especially in 
samples taken two or three days after trauma, pro- 
teolytic degradation of the PIIINP molecules can- 
not be ruled out completely, indicating that the 
split products had not been recognized by our test 
system highly specific for the intact Col 1-3 mole- 
cule. Due to experimental limitations in our labo- 
ratory such split products cannot as yet be identi- 
fied by other methods. However, two facts contra- 
dict the supposition of proteolytic degradation of 
the PIIINP molecules in vivo by elastase. First, 
there is no quantitative correlation (=0.055, r- 
squared=0.003) between the corresponding elas- 
tase and PIIINP levels in the synovial fluids taken 
during the early posttraumatic phase (Fig. 1). Sec- 
ond, highly elevated PIIINP levels have been mea- 
sured by several authors [8, 10, 11, 12] in synovial 
fluids of patients suffering from inflammatory 
rheuamtic disorders, despite the fact that other au- 
thors have also proven extremely elevated extracel- 
lular elastase levels in snyovial fluids of patients 
with such diseases [15, 16]. 
Therefore, the results of our pilot study can 
be summarized as follows: PMN-E as a nonspecif- 
ic mediator of local inflammation and PIIINP as 
a presumable marker of repair or fibrosis, respec- 
tively, have been determined in 38 traumatic knee 
joint effusions induced by acute or chronic sports 
injuries. The results how that traumatic knee joint 
effusions contain 
1. high concentrations of PMN-E (up to 5,400 ng/ 
ml) and low concentrations ( < 13 U/ml) of PIIINP 
in case of acute injury (group I patients) 
2. low concentrations of PMN-E (up to 330 ng/ml) 
and high concentrations (up to 133U/ml) of 
PIIINP in case of chronic injury (group II and III 
patients). 
The results also demonstrate hat the posttraumat- 
ic period is characterized by 
1. PMN-E" high increasing levels during the first 
24 hours, rapidly decreasing levels within 48 hours, 
no change after the 4th posttraumatic day 
2. PIIINP: continuously increasing levels from the 
4th posttraumatic day up to the first posttraumatic 
week; highly elevated levels in case of degenerative 
lesions. 
Due to the differential patterns of PMN-E and 
PIIINP concentrations in knee joint effusions, the 
measurement of both parameters together may be 
useful in estimating the period between trauma nd 
first treatment (aspiration of effusion). In this way 
it should be possible to detect degenerative lesions, 
which seem to be characterized by low levels of 
PMN-E and high levels of PIIINP. To confirm 
these conclusions, we are currently performing a
more extended study, investigating also serial syno- 
vial samples from individual patients. 
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